Candel Therapeutics Inc (CADL) Institutional Ownership Tracker (Q2 2026)

CADL ranks #3837 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CADL is a top-conviction position for Acorn Capital Advisors, LLC — at 9.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CADL belongs to FMR LLC, but the position matters far more to Acorn Capital Advisors, LLC, who has 9.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its CADL position for two straight quarters, increasing it by $66.7M to reach $113.2M today.

Two Sigma Investments, LP has trimmed its CADL position for two straight quarters, cutting it by $223.4K while still holding $337.1K.

CADL is up 2.7% today, and institutions have been net buyers of $104.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CADL reported a net loss of $88.5M over the trailing twelve months.

• Not yet profitable — net loss of $88.5M over the trailing twelve months
• Revenue declined 0.0% year over year
• Net income declined year over year, from -$22.1M to -$88.5M
• Operating cash flow was negative, using $38.3M in cash
• Current ratio of 13.49x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.41x equity — within a conventional range